Gynecologic Cancer

Gynecologic Cancer

Chemo After Chemoradiation Does Not Extend Survival in Cervical Cancer

Adding chemotherapy after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and it also leads to additional side effects.

Oncology Times - Latest Articles
Support Vector Machine Model Predicts Dose for Organs at Risk in High-Dose Rate Brachytherapy of Cervical Cancer

This study aims to establish a support vector machine model to predict the dose for organs at risk in intracavitary brachytherapy planning for cervical cancer with tandem and ovoid treatments.

Frontiers in Oncology
Identification of Methylation-Driven Genes Prognosis Signature and Immune Microenvironment in Uterus Corpus Endometrial Cancer

This study examines whether abnormal DNA methylation can predict the prognosis of uterus corpus endometrial cancer and reflect the patient's tumor immune microenvironment.

Cancer Cell International

Other HPV-Related Cancers Set to Overtake Cervical Cancer by 2025

The incidence of other HPV-associated cancers is rising and could soon surpass cervical cancer, a researcher told a press briefing held in advance of the 2021 ASCO Annual Meeting. 

Oncology Times - Latest Articles
CDC Notes Sharp Declines in Breast and Cervical Cancer Screening


The data show the total number of screenings funded by the NBCCEDP declined by 87% for breast cancer screening and by 84% for cervical cancer screening in April 2020 in comparison...

Factors Influencing the Discordancy Between Intraoperative Frozen Sections and Final Paraffin Pathologies in Ovarian Tumors

Study investigators examine the pre-operative clinical factors and ultrasonographic features that influence the accuracy of the intraoperative frozen section of ovarian tumors.

Frontiers in Oncology
Identifying & Managing Symptoms in Epithelial Ovarian Cancer

At the ASCO 2021 Annual Meeting, researchers highlighted the importance of a targeted approach to symptom management for epithelial ovarian cancer patients undergoing evaluation and treatment.

Oncology Times - Latest Articles
Machine Learning-Based Prediction of Survival Prognosis in Cervical Cancer

The aim of this study is to improve forecasting capability by developing a miRNAs-based machine learning survival prediction model.

BMC Bioinformatics
Radiation Therapy for Vaginal and Perirectal Lesions in Recurrent Ovarian Cancer

This study determines that radiation to treat locally recurrent vaginal/perirectal lesions in heavily pre-treated ovarian cancer patients is safe and may effectively provide in-field control.

Gynecology Oncology Reports
Survival Outcomes in Patients With 2018 FIGO Stage IA2–IIA2 Cervical Cancer Treated With Laparoscopic Versus Open Radical Hysterectomy

The objective of the study is to compare the survival and recurrence outcomes between open and laparoscopic RH for stage IA2-IIA2 cervical cancer based on...

Frontiers in Oncology
Metabolic Inhibitor Shows Antitumor Effects in Ovarian Patients

The glutaminase inhibitor IACS-6274 appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial.

Oncology Times - Latest Articles
Lack of Standardized Screening Linked to Increased Incidence of Many HPV-Related Cancers

While the annual incidence of cervical cancer in the US is on the decline, the incidence of other cancers related to HPV continues to increase, according to a study being presented at the 2021 ASCO

Cancer Therapy Advisor
Overexpression of LINC00673 Promotes the Proliferation of Cervical Cancer Cells

This study examines the expression of LINC00673 in cervical cancer and cervical intraepithelial neoplasia and explores the role of LINC00673 in the development of cervical cancer.

Frontiers in Oncology
ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment

Given the importance of the immune-related tumor microenvironment in ovarian cancer, investigating tumor-immune interactions and identifying novel prognostic and therapeutic targets in SOC is a...<

Frontiers in Oncology
Study Finds Ixabepilone Plus Bevacizumab Active in Platinum-Resistant or Recurrent Ovarian Cancer

The addition of bevacizumab to ixabepilone could be a promising treatment strategy for a group of patients with cancer currently lacking therapeutic options, according to data presented during the

The ASCO Post
Efficacy and Safety of Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

This study evaluates the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody–drug conjugate, in this patient population.

The Lancet Oncology
In Gynecologic Cancers, Who Can Safely Undergo Fertility-Sparing Surgery?

Traditional surgeries for gynecologic cancers can be lifesaving, but for younger women they can also cause infertility or induce surgical menopause.

Oncology Times - Latest Articles
Adjuvant Therapy Benefit Questioned in POLE-Mutated Endometrial Cancer

An individual patient data meta-analysis failed to demonstrate that receipt of adjuvant therapy provided a clear benefit for women with POLE-mutated endometrial cancer.

Cancer Therapy Advisor
Tisotumab for Advanced Cervical Cancer Awaiting Approval

Tisotumab vedotin, an investigational antibody drug conjugate directed against tissue factor, has shown promise for patients with recurrent or metastatic cervical cancer.

Outcomes With MRI-Based Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer

In this study, Pötter et al find that MRI-based image-guided adaptive brachytherapy is associated with a high rate of long-term local disease control and...

The ASCO Post
Genome-Wide Association Study of Variants Linked to Cervical Preinvasive and Invasive Disease

Bowden et al identify six independent variants among the PAX8, CLPTM1L, and HLA genes that are associated with risk for invasive cervical cancer or cervical intraepitheli

The ASCO Post
Secondary Cytoreduction Followed By Chemotherapy Versus Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer (SOC-1)

Study investigators assess the efficacy of secondary cytoreduction plus chemotherapy versus chemotherapy alone in this patient population.

The Lancet Oncology
Patients With Ovarian Cancer Face an Increased Risk of Mental Illness

Women diagnosed with ovarian cancer were more than three times more likely than the general public to be diagnosed with anxiety, depression, and adjustment disorder...

The ASCO Post
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer

The combination of lenvatinib, a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3 kinases, and pembrolizumab significantly improved multiple outcomes compared with standard single-agent CT in...

The ASCO Post
Overall Survival With Olaparib vs Placebo Maintenance in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and BRCA1/2 Mutation

The phase III SOLO2/ENGOT-Ov21 trial has shown a large numeric but statistically nonsignificant improvement in the secondary endpoint of overall survival with olaparib tablet maintenance therapy vs

The ASCO Post
Significance of EZH2 Expression in Endometrial Cancer

To identify new targets, researchers have explored the relevance of epigenetic modifiers in cancer therapeutics. One such potential candidate is enhancer of zeste homolog 2 (EZH2). 

Oncology Times - Latest Articles
MRI-Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer (EMBRACE-I)

This study reports on EMBRACE-I, which aims to evaluate local tumor control and morbidity after chemoradiotherapy and MRI-based IGABT.

The Lancet Oncology
Hormonal IUD May Be a Potential Nonsurgical Treatment for Early Endometrial Cancer or Precancer

An intrauterine device, or IUD, that releases the hormone levonorgestrel appears to be an effective treatment for endometrial precancer and early-stage endometrial cancer. 

The ASCO Post
Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer

The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer.

The ASCO Post
Frailty May Impact Surgical Outcomes in Patients With Ovarian Cancer

Frailty may be a better predictor of poor surgical outcomes in patients with ovarian cancer than age, according to two studies reported at the SGO 2021 Virtual Annual Meeting on Women’s Cancer.

The ASCO Post
Phase III ARIEL4 Trial Confirms Benefit of Rucaparib in BRCA-Mutated Relapsed Ovarian Cancer

In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP inhibitor rucaparib led to a significant improvement in progression-free survival compared with...

The ASCO Post
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation

The aim of this final analysis is to investigate the effect of olaparib on overall survival.

The Lancet Oncology
The Impact of Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

The aim of the present meta-analysis is to further update the role of PLD in the treatment of recurrent ovarian cancer.

Journal of Ovarian Research

source list reference